LDL-C calculator

* This calculator is based on the average LDL-C reduction achieved in trials with a given therapy and therefore shows average results from lipid lowering therapy. Of note, trial populations usually have better adherence than in real-world practice. The results of untreated LDL-C calculation can be inflated by hyporesponse or non-adherence to therapy by the patient. Therefore, the calculator automatically gives an error when the calculated LDL-C exceeds 10 mmol/L. Levels this high are only seen in severely affected (homozygous) familial hypercholesterolemia patients.

  • Statins: based on the mean LDL-C reduction per statin and dose described in1
  • Ezetimibe on top of statins: based on the mean LDL-C reduction in the ENHANCE2 and IMPROVE-IT3 trials (20%)
  • Ezetimibe as monotherapy: based on a meta-analysis of randomized controlled trials4 (21%)
  • PCSK9 inhibition on top of any lipid lowering therapy: based on the mean LDL-C in the FOURIER5 and ODDYSEY6 trials (53%)
  • PCSK9 inhibition monotherapy: based on a meta-analysis of randomized controlled trials4 (57%)
  • PCSK9 inhibition in combination with ezetimibe: based on a meta-analysis of randomized controlled trials4 (69%)
  • Bempedoic acid on top any lipid lowering therapy: based on the average LDL-C reduction in the CLEAR Harmony and CLEAR Wisdom studies7 (18%)
  • Bempedoic acid without statin therapy: based on the average LDL-C reduction in the CLEAR Outcomes study8 (21%)
  • Bempedoic acid in combination with ezetimibe, irrespective of statin use: based on the LDL-C reduction observed in a randomized controlled trial9 (36%)

 

1. Besseling, J. et al. Atherosclerosis 233, 219–223 (2014)
2. Kastelein, J. J. P. et al. N. Engl. J. Med. 358, 1431–1443 (2008)
3. Cannon, C. P. et al. N. Engl. J. Med. 372, 2387–2397 (2015)
4. Lipinski, M. J. et al., Eur. Heart J. 37, 536–545 (2016)
5. Sabatine, M. S. et al. N. Engl. J. Med. 376, 1713–1722 (2017)
6. Schwartz, G. G. et al. N. Engl. J. Med. 379, 2097-2107 (2018)
7. Ballantyne, C. M. et al., Cardiovasc. Drugs Ther. 35, 853–864 (2021)
8. Nissen, S. E. et al. N. Engl. J. Med. 388, 1353-1364 (2023)
9. Ballantyne, C. M. et al., Eur. J. Prev. Cardiol. 27, 593–603 (2020)

These calculations are intended for educational use by healthcare professionals. Calculations must be re-checked and should not be used to guide patient care or clinical judgment (Disclaimer).

Educational purposes only

The content of this website is intended for use by healthcare professionals and provides for educational purposes. The content of this website does not provide medical advice relating to an individual case or a patient, nor does it offer medical or diagnostic services. We do not guarantee that the information we provide will meet your health or medical requirements. It is up to you to contact a health professional if you have any concerns about your health.